NASDAQ : BDSX
Biodesix, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 24.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 260.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 245.37M |
| Enterprise Value | 287.17M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 10.55M |
| Shares Outstanding | 10.55M |
| Shares Change (YoY) | +21.27% |
| Shares Change (QoQ) | +6.63% |
| Owned by Insiders (%) | 40.86% |
| Owned by Institutions (%) | 29.39% |
| Float | 4.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.38 |
| Forward PS | 2.02 |
| PB Ratio | 26.83 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.85 |
| Quick Ratio | 2.56 |
| Debt / Equity | 7.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.54 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -540.01% |
| Return on Assets (ROA) | -14.05% |
| Return on Invested Capital (ROIC) | -16.68% |
| Return on Capital Employed (ROCE) | -25.72% |
| Weighted Average Cost of Capital (WACC) | 7.65% |
| Revenue Per Employee | $308,201 |
| Profits Per Employee | -$83,120 |
| Employee Count | 334 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 12.86 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +255.58% |
| 50-Day Moving Average | 26.46 |
| 200-Day Moving Average | 18.67 |
| Relative Strength Index (RSI) | 43.98 |
| Average Volume (20 Days) | 82,625 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 209,504 |
| Short Previous Month | 201,849 |
| Short % of Shares Out | 1.99% |
| Short % of Float | 4.21% |
| Short Ratio (days to cover) | 2.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 102.94M |
| Gross Profit | 84.93M |
| Operating Income | -20.58M |
| Pretax Income | -27.76M |
| Net Income | -27.76M |
| EBITDA | -15.01M |
| EBIT | -20.58M |
| Loss Per Share | -$3.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 30.00M |
| Total Debt | 71.80M |
| Net Cash | -41.80M |
| Net Cash Per Share | -$3.96 |
| Equity (Book Value) | 9.14M |
| Book Value Per Share | 0.87 |
| Working Capital | 28.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.83M |
| Capital Expenditures | -412,000 |
| Depreciation & Amortization | 5.58M |
| Net Borrowing | -15,000 |
| Free Cash Flow | -20.24M |
| FCF Per Share | -$1.92 |
Margins
| Measure | Value |
|---|
| Gross Margin | 82.50% |
| Operating Margin | -19.99% |
| Pretax Margin | -26.97% |
| Profit Margin | -26.97% |
| EBITDA Margin | -14.58% |
| EBIT Margin | -19.99% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.27% |
| Shareholder Yield | -21.27% |
| Earnings Yield | -13.44% |
| FCF Yield | -8.25% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $39.00 |
| Price Target Difference | 67.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 20.85% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.16 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |